樂
樂觀
樂觀 · 25%PHGE
$0.42
情境價格
$1.850
+0.263 (+14.20%)收盤時
Loading chart…
- 最高
- 2.158
- 開盤
- 1.660
- 成交量加權均價
- 1.89
- 成交量
- 3.40M
- 市值
- 23.61M
- 最低
- 1.650
- 成交金額
- 6.41M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
Tessera Defense and Homeland Security Inc., formerly BiomX Inc., is a technology company focused on defense and homeland security. The Company, through its subsidiaries and investments, develops and deploys threat detection, AI-powered analysis and related technologies for defense, security and critical infrastructure customers.
AI 分析 of BiomX Inc (PHGE)
持有Biomx Inc (PHGE) is currently not a strong buy due to its significant losses and lack of revenue. The stock is trading at $0.15, down 93.10% year-to-date, indicating severe financial distress. Although the recent acquisition news may provide some positive outlook, the company reported a net income loss of $37.72 million in Q2 2026, which raises concerns about its financial stability. The RSI is at 66.55, suggesting it is nearing overbought territory, which could lead to a pullback. The main risk is the ongoing negative earnings trend, with a forward P/E ratio of 0, indicating no expected profitability in the near future.
估值指標
BiomX Inc（PHGE）目前預期本益比為 0.00，5 年平均預期本益比為 -0.88。
Alphio AI 對 PHGE 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
事件時間軸
資訊
3.509-04NewsfilterBiomX to Rebrand as Tessera, Launches No-Code AI Command Platform
- 8.509-01Newsfilter
BiomX to Rebrand as Tessera Defense and Homeland Security Inc.
- 7.508-14Newsfilter
BiomX Subsidiary Secures $300,000 Defense Order
8.508-05seekingalphaBiomX Acquires 10% Stake in Motomea to Enhance Drone Testing Capabilities
8.507-28GlobenewswireBiomX Amends Terms of Zorronet Acquisition
PHGE 常見問題 —— 由 Alphio AI 解答
Tessera Defense and Homeland Security Inc., formerly BiomX Inc., is a technology company focused on defense and homeland security. The Company, through its subsidiaries and investments, develops and deploys threat detection, AI-powered analysis and related technologies for defense, security and critical infrastructure customers. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Biomx Inc (PHGE) is currently not a strong buy due to its significant losses and lack of revenue. The stock is trading at $0.15, down 93.10% year-to-date, indicating severe financial distress. Although the recent acquisition news may provide some positive outlook, the company reported a net income loss of $37.72 million in Q2 2026, which raises concerns about its financial stability. The RSI is at 66.55, suggesting it is nearing overbought territory, which could lead to a pullback. The main risk is the ongoing negative earnings trend, with a forward P/E ratio of 0, indicating no expected profitability in the near future.
社群
更多 ↗暫無貼文
註冊或登入後參與討論本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。